As widely expected, Array Biopharma Inc.'s combo regimen of an oral, small-molecule BRAF kinase inhibitor and an oral, small-molecule MEK inhibitor cleared the FDA for use in patients with unresectable or metastatic melanoma with BRAFV600E or BRAFV600K mutations, a first approval that could prove only the tip of the iceberg for the Boulder, Colo.-based firm's development of two- and three-drug combos to follow.